Biocon shares decline despite analyst optimism on Biologics merger deal
The pharmaceutical major on December 6 unveiled plans to acquire the remaining 23.3% minority stake in BBL through a combination of share swaps and cash, valuing the biologics unit at $5.5 billion Read More | Source: The Hindu Business Line